| abstract |
The present invention relates to compounds of formula (I): Wherein Q is selected from O or S; L is a saturated or unsaturated, optionally substituted C 1 -C 12 hydrocarbylene group optionally containing one or more heteroatoms N, O or S; R 1 is -NR 3 R 4 , -OR 5 ,-(C = NR 6 ) R 7 ,-(CO) R 8 , -CN, -N 3 , quaternary ammonium group or an optionally substituted heterocycle; R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently hydrogen, or a saturated or unsaturated, optionally substituted C 1 optionally containing one or more heteroatoms N, O or S. -C 10 hydrocarbyl group; Optionally L and R 3 , or L and R 4 , or R 3 and R 4 , or L and R 5 , or L and R 6 , or L and R 7 , or R 6 and R 7 , or L and R 8 Silver, together with the atom (s) to which they are attached, can form 3- to 12-membered, saturated or unsaturated, optionally substituted cyclic groups; And R 2 is a cyclic group substituted at the α-position, R 2 may be optionally further substituted; The atom of L attached to the sulfur atom of the sulfonylurea group is a carbon atom, not a ring atom of a heterocyclic or aromatic group. The present invention also relates to salts, solvates and prodrugs of such compounds, pharmaceutical compositions comprising such compounds, and in particular the use of such compounds in the treatment and prevention of medical disorders and diseases caused by inhibition to NLRP3. |